Clinical trials: Epileptic
Tuberous Sclerosis Complex
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Study design is a Phase IIb prospective multi-center, randomized, placebo-controlled, double-blind clinical trial. The goal will be to enroll 80 infants with Tuberous Sclerosis Complex who are less than 6 months of age prior to…
- Trial name
- NCT02849457
- Testing
- Early Vigabatrin
- Where
- 13 sites in United States
- Volunteers
- 84 people
- Sponsor
- Martina Bebin
Epilepsy, Partial Onset Seizures
A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
The purpose of this study is to evaluate the efficacy and safety of 200 and 400 mg/day of orally administered Lacosamide as adjunctive therapy compared with placebo in Japanese and Chinese adults with uncontrolled Partial-Onset…
- Trial name
- NCT01710657
- Testing
- Lacosamide 50 mg, Lacosamide 100 mg
- Where
- 76 sites in China, Japan
- Volunteers
- 548 people
- Sponsor
- UCB Pharma SA
Partial Epilepsies, Partial Onset Seizures
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of this study is to allow eligible subjects from the parent study, SP925 [NCT00655551] to continue lacosamide and to obtain additional long-term safety data
- Trial name
- NCT00655486
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy, Tonic-clonic
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.
- Trial name
- NCT00150813
- Testing
- Levetiracetam
- Where
- 21 sites in Czechia, Hungary and 2 more
- Volunteers
- 66 people
- Sponsor
- UCB Pharma SA
Epilepsy
A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode
The purpose of this study is to determine the pharmacokinetics of Diazepam Nasal Spray following a single dose in epileptic patients experiencing a seizure episode.
- Trial name
- NCT01417078
- Testing
- Diazepam
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Acorda Therapeutics
Epilepsy
An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls. The trial consisted of a screening visit, a treatment phase and a follow-up visit.
- Trial name
- NCT02281526
- Testing
- BIA 2-093
- Where
- South Africa
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
To evaluate the efficacy of open-label ganaxolone as adjunctive therapy for uncontrolled seizures in female children with PCDH19 mutation and other rare genetic epilepsies in an open-label proof-of-concept study.
- Trial name
- NCT02358538
- Testing
- Ganaxolone
- Where
- 10 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- Marinus Pharmaceuticals
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Epilepsies, Partial
Open-label Extension to Protocol 1042-0600
To allow open-label extension to patients who have completed Protocol 1042-0600.
- Trial name
- NCT00512317
- Testing
- ganaxolone
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy, Partial Seizure Disorder
Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.
- Conditions
- Epilepsy, Partial Seizure Disorder, Epilepsies, Partial, Complex Partial Seizure Disorder
- Trial name
- NCT00537940
- Testing
- Pregabalin, Gabapentin
- Where
- 8 sites in Costa Rica, El Salvador and 2 more
- Volunteers
- 482 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
The Sponsor wishes to develop brivaracetam as an anti-epileptic treatment in subjects 16 years and older with epilepsy. This study permits continued access to treatment for subjects who participated in a previous epilepsy study.
- Trial name
- NCT00761774
- Testing
- Brivaracetam
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 108 people
- Sponsor
- UCB Pharma
Status Epilepticus
Randomized Therapy In Status Epilepticus
This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
- Trial name
- RAISE (NCT04391569)
- Testing
- Ganaxolone
- Where
- 74 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
The purpose of this observational study is to broaden the knowledge of the known safety and efficacy profile of Keppra® (Levetiracetam) oral solution in epileptic infants younger than 12 months when treated according to routine…
- Trial name
- NCT01210690
- Where
- 27 sites in France, Germany and 5 more
- Volunteers
- 101 people
- Sponsor
- UCB Pharma
Seizures
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
- Trial name
- NCT04686786
- Testing
- CVL-865
- Where
- 56 sites in United States, Australia and 5 more
- Volunteers
- 105 people
- Sponsor
- AbbVie
Epilepsy
Flexible Representation of Speech
The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane.
- Trial name
- NCT05209386
- Testing
- Dimension-Based Statistical Learning
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Pittsburgh
Epilepsy
Pilot Study of Melatonin and Epilepsy
The prevalence of epilepsy is 1% in the USA. About 30% of epilepsy patients eventually become refractory to medical treatment. Co morbid conditions are becoming as important as seizure control as these affect overall wellbeing.
- Trial name
- NCT00965575
- Testing
- Melatonin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hypertension, Brain Tumor
A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
This protocol describes a study to gain experience in the use of Clevidipine for perioperative blood pressure control in patients undergoing craniotomy for brain tumor or epilepsy focus resection.
- Conditions
- Hypertension, Brain Tumor, Epilepsy
- Trial name
- NCT00952081
- Testing
- Clevidipine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Epilepsy
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
Study is conducted to evaluate the long-term safety and tolerability of lacosamide (LCM) in patients receiving LCM in SP0994 [NCT01465997].
- Trial name
- NCT02582866
- Testing
- Lacosamide
- Where
- 46 sites in Bulgaria, Finland and 13 more
- Volunteers
- 106 people
- Sponsor
- UCB Biopharma S.P.R.L.
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
- Trial name
- NCT00368251
- Testing
- BRV 2.5 mg, BRV 25 mg, BRV 50 mg
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma
Epilepsy
Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation
Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 10 to 14 days or more.
- Trial name
- NCT02305329
- Testing
- BIA 9-1067
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.